BiondVax Announces First Quarter 2022 Financial Results and Provides Business Update
JERUSALEM, June 1, 2022 /PRNewswire/ — BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceuticals company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today published its first quarter financial results for the quarter ended March 31, 2022 and provided a business update.
Business Update
- Development of the NanoAb program is proceeding according to plan:
o Demonstrated successful technology transfer from the Max Planck Institute for Multidisciplinary Sciences (MPG) to BiondVax’s manufacturing facility in Jerusalem. Testing showed that BiondVax was able to successfully manufacture its first exclusively licensed NanoAb for the treatment of COVID–19 and demonstrated strong neutralization of live COVID–19 virus in–vitro at levels similar to those demonstrated by NanoAbs originally produced at MPG.
o …
